021-51111890
购物车（）
sales@molnova.cn
AGI-1067
CAS No. 216167-82-7
AGI-1067 ( Succinobucol;AGI 1067;AGI1067 )
产品货号. M13448 CAS No. 216167-82-7
AGI-1067 (Succinobucol) is a potent inhibitor of TNF-α-inducible expression of VCAM-1, MCP-1 and E-selectin (IC50=6,10 and 25 uM).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥381 | 有现货 |
|
| 10MG | ￥648 | 有现货 |
|
| 25MG | ￥1320 | 有现货 |
|
| 50MG | ￥2252 | 有现货 |
|
| 100MG | ￥3856 | 有现货 |
|
| 500MG | ￥8505 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AGI-1067
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述AGI-1067 (Succinobucol) is a potent inhibitor of TNF-α-inducible expression of VCAM-1, MCP-1 and E-selectin (IC50=6,10 and 25 uM).
-
产品描述AGI-1067 (Succinobucol) is a potent inhibitor of TNF-α-inducible expression of VCAM-1, MCP-1 and E-selectin (IC50=6,10 and 25 uM) with concurrent antioxidant and lipid-modulating properties; inhibits atherosclerosis in LDL receptor-deficient and apolipoprotein E-deficient mice, also reduces VCAM-1 and MCP-1 mRNA levels in lungs of LPS-stimulated mice; inhibits atherosclerosis not only via its lipid-lowering effects but also by having direct anti-inflammatory effects on the vessel wall.Diabetes Phase 3 Clinical
-
同义词Succinobucol;AGI 1067;AGI1067
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域Metabolic Disease
-
适应症Diabetes
化学信息
-
CAS Number216167-82-7
-
分子量616.92
-
分子式C35H52O5S2
-
纯度>98% (HPLC)
-
溶解度DMSO: Soluble （ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESO=C(O)CCC(OC1=C(C(C)(C)C)C=C(SC(C)(SC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)C)C=C1C(C)(C)C)=O
-
化学全称4-(4-((1-((3,5-bis(1,1-Dimethylethyl)-4-hydroxyphenyl)sulfanyl)-1-methylethyl)sulfanyl)-2,6-bis(1,1-dimethylethyl)phenoxy)-4-oxobutanoic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Sundell CL, et al. J Pharmacol Exp Ther. 2003 Jun;305(3):1116-23.
2. Meng CQ, et al. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2545-8.
3. Tardif JC, et al. Circulation. 2003 Feb 4;107(4):552-8.
4. Kunsch C, et al. J Pharmacol Exp Ther. 2004 Mar;308(3):820-9.
2. Meng CQ, et al. Bioorg Med Chem Lett. 2002 Sep 16;12(18):2545-8.
3. Tardif JC, et al. Circulation. 2003 Feb 4;107(4):552-8.
4. Kunsch C, et al. J Pharmacol Exp Ther. 2004 Mar;308(3):820-9.
产品手册
关联产品
-
(Z)-1-Methyl-2-(unde...
(Z)-1-Methyl-2-(undec-6-enyl)quinolin-4(1H)-one shows strong inhibitory activity on leukotriene biosynthesis in human polymorphonuclear granulocytes, and it is very effective against mycobacteria.
-
Oxytroflavoside A
The branches of Rhamnus cathartica.
-
NVP-CGM097
NVP-CGM097 is an effective and specific MDM2 inhibitor (IC50: 1.7 nM for hMDM2).
